Abstract
Structure-based rational design has been considered as a promising approach to design novel proteins. For this purpose, we designed artificial anticoagulant proteins that are able to target Factor Xa (FXa) using a functional motifgrafting approach. The motif corresponded to the residues Cys15 to Cys42 of Ancylostoma caninum anticoagulant peptide 5 (AcAP5), a potent FXa inhibitor. By screening of the Protein Data Bank (PDB) using Vector Alignment Search Tool (VAST, search for three-dimensional scaffolds in protein structures), we screened scaffolds as hosts to reproduce the functional topology of this motif. Three designed artificial chimeric proteins were expressed and purified to test their FXainhibiting ability. One of the recombinant proteins, pep3, was found to inhibit FXa with strong activity (IC50 of 152 nM) in vitro. Moreover, pep3 inhibited arterial thrombosis formation in rats with uniform potency compared with natural AcAP5. Therefore, our data demonstrate that motif-grafting is a useful tool to engineer novel artificial anticoagulant proteins.
Keywords: AcAP5, anticoagulant, Factor Xa, inhibitor, motif-grafting, VAST.
Protein & Peptide Letters
Title:Engineering Novel Anticoagulant Proteins by Motif Grafting
Volume: 21 Issue: 2
Author(s): Yuanjun Zhu, Aihua Liu, Xiaoyan Liu and Yinye Wang
Affiliation:
Keywords: AcAP5, anticoagulant, Factor Xa, inhibitor, motif-grafting, VAST.
Abstract: Structure-based rational design has been considered as a promising approach to design novel proteins. For this purpose, we designed artificial anticoagulant proteins that are able to target Factor Xa (FXa) using a functional motifgrafting approach. The motif corresponded to the residues Cys15 to Cys42 of Ancylostoma caninum anticoagulant peptide 5 (AcAP5), a potent FXa inhibitor. By screening of the Protein Data Bank (PDB) using Vector Alignment Search Tool (VAST, search for three-dimensional scaffolds in protein structures), we screened scaffolds as hosts to reproduce the functional topology of this motif. Three designed artificial chimeric proteins were expressed and purified to test their FXainhibiting ability. One of the recombinant proteins, pep3, was found to inhibit FXa with strong activity (IC50 of 152 nM) in vitro. Moreover, pep3 inhibited arterial thrombosis formation in rats with uniform potency compared with natural AcAP5. Therefore, our data demonstrate that motif-grafting is a useful tool to engineer novel artificial anticoagulant proteins.
Export Options
About this article
Cite this article as:
Zhu Yuanjun, Liu Aihua, Liu Xiaoyan and Wang Yinye, Engineering Novel Anticoagulant Proteins by Motif Grafting, Protein & Peptide Letters 2014; 21 (2) . https://dx.doi.org/10.2174/092986652102131226112049
DOI https://dx.doi.org/10.2174/092986652102131226112049 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Characteristics and CT Imaging Features of COVID-19 on Admission: A Retrospective Study
Current Medical Imaging Chemoinfectomics in Drug Design and Development
Anti-Infective Agents Cyclophilin function in Cancer; lessons from virus replication
Current Molecular Pharmacology Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Free ISG15 and Protein ISGylation Emerging in SARS-CoV-2 Infection
Current Drug Targets A Multi-Scale Parameterization Approach of Peptides for Quantitative Sequence-Activity Models
Protein & Peptide Letters Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials
Mini-Reviews in Medicinal Chemistry Phytochemical Informatics and Virtual Screening of Herbs Used in Chinese Medicine
Current Pharmaceutical Design Effects of Salinomycin on Cancer Stem Cell in Human Lung Adenocarcinoma A549 Cells
Medicinal Chemistry Synthetic Genomics and Synthetic Biology Applications Between Hopes and Concerns
Current Genomics Chemodiversity in Freshwater and Terrestrial Cyanobacteria – A Source for Drug Discovery
Current Drug Targets Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets Immuno-Informatics Quest against COVID-19/SARS-COV-2: Determining Putative T-Cell Epitopes for Vaccine Prediction
Infectious Disorders - Drug Targets COVID-19 Impacts, Diagnosis and Possible Therapeutic Techniques: A Comprehensive Review
Current Pharmaceutical Design CT Diagnosis of Coronavirus Infection
Current Medical Imaging Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19
Current Cardiology Reviews Hydroxychloroquine Sulfate (Plaquenil): A Possible Candidate for Pandemic SARS-CoV-2 or (COVID-19) ?
Coronaviruses Selection of Active Antiviral Compounds Against COVID-19 Disease Targeting Coronavirus Endoribonuclease Nendou/NSP15 Via Ligandbased Virtual Screening and Molecular Docking
Letters in Drug Design & Discovery Editorial [Hot topic: Structural Genomics (Executive Editor: Yu Wai Chen)]
Infectious Disorders - Drug Targets Molecular Docking Studies of Bioactive Nicotiflorin against 6W63 Novel Coronavirus 2019 (COVID-19)
Combinatorial Chemistry & High Throughput Screening